





mRNA COVID-19 VACCINE ELIGIBILITY ALGORITHM FOR VACCINATORS

July 29, 2022. Produced by Meagan Vander Ploeg, Pandemic Task Force Coordinator (Weeneebayko Area Health Authority) in collaboration with Jacquelin Fleming-Hillyer, A/ Practice Consultant Public Health - Immunization File (FNIHB-OR, Indigenous Services Canada)



RECOMMENDED VACCINE AND DOSAGE	Age?						Age?			
	1st & 2nd dose	2nd dose	2nd dose	5-11:	12+:	30+:	12+:	30-69 Immuno-competent:	30+ Immuno-compromised:	70+:
	6 m.o. - 4 y.o.: Moderna 25mcg ^{5,6}	5 y.o. * & * Moderna for 1st: Moderna 25mcg ^{5,6}	6 y.o. * & * Moderna for 1st: Moderna 50mcg ^{5,6}	Pfizer 10mcg (0.2mL) ⁵	Pfizer 30mcg ^{5,7} (0.3mL)	Moderna 100mcg ⁶	Pfizer 30mcg ^{5,7} (0.3mL)	Moderna 50mcg ^{5,6}	Moderna 100mcg ^{5,6}	Moderna 100mcg ⁶

Using our algorithm? Let us know!
 Visit: <https://forms.office.com/r/4RCF2uMTbw>
 or scan the QR code with your smartphone.
 You can also use the QR code to ensure you are using the most up-to-date version of the algorithm!



¹Counsel patients on the benefits of recommended intervals as outlined above. Patients may receive vaccine sooner with informed consent as follows: 1st & 2nd dose Primary Series: may have at product interval (6m.o.-5 y.o. 28+ days Moderna; 6+ y.o. 21+ days Moderna, 5+ y.o. 19+ days Pfizer). 3rd Dose in 3-Dose Primary Series (immunocompromised): 28+ days all mRNA products. **Booster Doses:** 84+ days.

²For the purposes of this tool, "COVID-19 Infection" date means date of COVID-19 symptom onset, or date of positive COVID-19 test if asymptomatic.

³For the purposes of this tool, "immunocompromised" includes patients who meet any of the immunocompromised criteria listed in the Government of Canada's COVID-19 Vaccine: Canadian Immunization Guide as referenced in the Ontario Ministry of Health COVID-19 Vaccination Administration Guidance: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#a6.4.considerations>. In these populations, a 3rd dose is considered part of the PRIMARY series; use full doses

⁴In children with a history for MIS-C, vaccination should be deferred until clinical recovery has been achieved or ≥90 days since diagnosis of MIS-C, whichever is longer.

⁵Patients age 5-29 should be counselled that Pfizer is the preferred product for their age demographic unless they are 5-6 y.o. and received Moderna as their first dose. In the latter case, they should be counselled to continue with the same product. In the former case, if they still desire to get primary series or booster doses of Moderna even after counselling and give informed consent, vaccinators should consult with their Clinic Team Lead prior to administration. The fact that counselling occurred should also be noted in COVAX comments. Please consult Ontario Ministry of Health Vaccine Administration Guidance for COVID-19 vaccine dosing not included in the recommended dosing above.

⁶Moderna vaccine comes in various concentrations, therefore volume (i.e. mL) dosage amounts are not provided. For 50mcg doses, the red or blue cap product may be used.

⁷Pfizer Purple Cap (requires dilution) or Pfizer Grey Cap (do NOT dilute) may be used.

Acronyms: Hx: History; FNIM: First Nations, Inuit and Metis; LTC: Long Term Care; RH: Retirement Home; M.o.: months old; Y.o.: years old; Y: Yes, N: No; >: greater than.